Vireo Growth Q3 2026 Results: Revenue Jumps 177% to $254 Million, Adds 33 Florida Dispensaries

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

Vireo Growth's Q3 2026 revenue jumps 177% to $253.7 million on acquisitions, but adjusted EBITDA margin falls to 16.8% from 27.7%. The FLUENT deal, closed November 9, lifts its Florida network to about 74 dispensaries.

• Operators: Consolidation is building scale but squeezing margins. Pro forma retail revenue grew only about 4%, a same-store proxy, so integration and operating efficiency matter more than store count, especially in Florida.
• Investors: Revenue growth is acquisition-driven while adjusted EBITDA margin shrinks. Q1 2027 guidance of $280-$300 million in revenue and $53-$56 million in adjusted EBITDA is the next test of whether profitability keeps pace with scale.
• Do now: Compare your own same-store sales and margin trends against acquired revenue, and check whether any high-interest debt, like Vireo's 15% seller note, could be refinanced at a lower fixed rate.

Short on time? You’re done. Want the numbers?Keep reading ↓

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) reported third-quarter 2026 revenue of $253.7 million, up 177% from $91.7 million a year earlier, as acquisitions continued to reshape the company’s operations across the U.S. cannabis industry.

The results, released Tuesday, come one day after Vireo completed its acquisition of FLUENT Corp., adding 33 dispensaries and expanding its Florida retail network to approximately 74 locations.

Vireo reported $42.7 million in adjusted EBITDA, up 68% year over year, while its adjusted EBITDA margin declined to 16.8% from 27.7%.

The company posted a net loss of $24 million, compared with a $26.3 million loss in the prior-year quarter.

Cannabis Revenue Doubles, but Margins Narrow

Of Vireo’s $253.7 million in quarterly revenue, $198.1 million came from cannabis operations, a 116% increase year over year. The remaining $55.6 million came from non-cannabis operations, including its agricultural supply business.

Gross profit reached $107.8 million, representing a 42.5% margin, compared with 40.8% a year earlier.

However, adjusted cannabis gross margin declined to 50.9% from 55.4%, while the consolidated adjusted EBITDA margin fell nearly 11 percentage points.

Sequentially, revenue increased 21% from $209.3 million in the second quarter, but adjusted EBITDA rose only 2.9%, to $41.5 million.

Vireo reported approximately 4% year-over-year growth in pro forma retail revenue, which management described as a proxy for same-store sales performance.

“The third quarter marked another important period of progress for Vireo as we continued executing our strategy of disciplined, capital-efficient consolidation,” CEO John Mazarakis said.

“With an annualized revenue run rate exceeding $1 billion, we have established significant scale, but our focus remains on leveraging that scale to drive stronger operating and financial performance.”

The $1 billion figure is an annualized run rate based on third-quarter revenue, not revenue already earned over a full year.

FLUENT Acquisition Expands Florida Operations

Vireo’s November 9 acquisition of FLUENT substantially increases its exposure to Florida’s medical cannabis market.

The transaction adds 33 dispensaries and approximately 117,000 square feet of cultivation and production capacity.

Combined with Vireo’s existing Green Dragon operations, the company now has approximately 74 operating dispensaries and 317,000 square feet of cultivation and manufacturing capacity in Florida.

“Florida is an important market for Vireo,” Mazarakis said in the acquisition announcement.

“We have already seen progress in operating efficiencies based on FLUENT’s implementation of an operating budget adopted by its board to streamline operations and optimize performance.”

The company also recently announced that all 41 of its existing state-licensed Florida medical cannabis dispensaries had received federal registrations from the Drug Enforcement Administration.

Separately, Vireo continues pursuing acquisitions in other states, including Ohio. Management said completing its announced transactions would bring the company’s network to approximately 270 dispensaries across 15 states.

Vireo Forecasts Up to $300 Million in Quarterly Revenue

Vireo issued guidance for the fourth quarter of 2026 and the first quarter of 2027.

For the fourth quarter, management expects revenue between $250 million and $265 million, with adjusted EBITDA between $45 million and $48 million.

The forecast includes FLUENT’s results beginning November 9, when the acquisition closed, but excludes other pending transactions.

For the first quarter of 2027, Vireo projects revenue of $280 million to $300 million and adjusted EBITDA of $53 million to $56 million.

At the midpoint, that represents approximately $290 million in quarterly revenue and $54.5 million in adjusted EBITDA.

Management also disclosed that pending acquisitions, had they closed before the beginning of the fourth quarter, could have contributed an additional $45 million to $55 million in revenue and $5 million to $6 million in adjusted EBITDA.

Cash, Debt and Financing

Vireo ended September with $106.8 million in cash, including restricted cash, and approximately $293 million in long-term debt.

The company generated $18.8 million in operating cash flow during the first nine months of 2026, compared with $15 million used in operating activities during the corresponding period of 2025.

Vireo also announced an $85 million asset-based revolving credit facility with Bank of Montreal for its non-cannabis agricultural supply business.

Following the quarter, the company secured a $60 million real estate loan at an 8.5% fixed interest rate, partially refinancing a $49 million seller note carrying 15% interest.

The refinancing lowers the interest rate on that portion of its borrowing, an important consideration for a company continuing to finance acquisitions and integration.

Vireo also repurchased approximately $2.5 million of its shares during the third quarter under a previously announced buyback program.

The next test for the company will be whether its expanded operations deliver improved margins and cash generation. Its acquisitions have already produced a much larger revenue base, but the latest results show that scale and profitability are not advancing at the same pace.

The financial implications of cannabis consolidation, access to capital, and regulatory change will be among the subjects discussed at IgniteIt’s Cannabis Capital & Policy Summit in Washington, D.C., on November 18.